Drug Trial Radar · NCT07579936
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Jul 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Salubris (Suzhou) Pharmaceutical Co., Ltd.
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
Conditions
- Postmenopausal Women With Osteoporosis
Interventions
SAL056 56.5μgDrug
SAL056 56.5μg administered once weekly for 8 weeks
Intervention Group 1Drug
Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks.
Intervention Group 2Drug
Teriparatide Injection daily formulation administered for 4 weeks, followed by SAL056 for 4 weeks.
Intervention Group 3Drug
SAL056 28.2μg administered twice weekly for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) between each intervention group and the control group during the treatment period,about 10weeksTime frame: during the treatment period,about 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.